Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00062426 · ClinicalTrials.gov registry record · Phase 3
Oxaliplatin and Bevacizumab (Avastin™) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal Cancer
A Phase 3 study, sponsored by Prologue Research International.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00062426: Completed Phase 3 study, sponsored by Prologue Research International.
NCT00062426 is a Phase 3 study that has completed, run by Prologue Research International. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00062426, a Phase 3 study, has completed, sponsored by Prologue Research International.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, fluorouracil, leucovorin, and capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different combinations may kill more tumor cells. Monoclonal antibodies, such as bevacizumab (Avastin™), can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. It is not yet known which regimen works better in treating advanced colorectal cancer. PURPOSE: This randomized phase III trial is to see if oxaliplatin and bevacizumab work better when combined with either fluorouracil and leucovorin or capecitabine in treating patients who have metastatic or recurrent colorectal cancer.
Interventions
- DRUG oxaliplatin
- DRUG fluorouracil
- DRUG capecitabine
- DRUG leucovorin calcium
- BIOLOGICAL bevacizumab
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-05 |
| Est. Completion | 2011-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00062426
The ClinicalTrials.gov registry entry for NCT00062426 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Prologue Research International, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which oxaliplatin is the first listed.
NCT00062426 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00062426 about?
NCT00062426 is a clinical study titled "Oxaliplatin and Bevacizumab (Avastin™) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal Cancer". RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, fluorouracil, leucovorin, and capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different combinations may kill more tumor cells. Monoclonal a...
What is the current status of trial NCT00062426?
This trial is currently completed. It is a Phase 3 study. The study started on 2003-05. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00062426?
The interventions under investigation include: oxaliplatin (DRUG), fluorouracil (DRUG), capecitabine (DRUG), leucovorin calcium (DRUG), bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00062426?
This trial is sponsored by Prologue Research International, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.